What is Insulin Autoimmune Syndrome (Hirata Disease)?
Insulin autoimmune syndrome (IAS), also known as Hirata disease, is a rare autoimmune disorder causing hyperinsulinemic hypoglycemia due to high-titer insulin autoantibodies that bind endogenous insulin and release it unpredictably, producing postprandial hyperglycemia followed by severe delayed hypoglycemia in individuals who have never received exogenous insulin. 1, 2
Pathophysiology
The disease mechanism involves a distinctive two-phase glycemic pattern:
- Postprandial phase: Insulin autoantibodies (IAA) sequester insulin secreted after meals, preventing it from binding its receptor, which may cause mild hyperglycemia 3
- Delayed hypoglycemic phase: Insulin dissociates from antibodies in an unregulated fashion hours later, independent of blood glucose levels, causing severe hypoglycemia typically in the late postprandial period 1
The antibodies are high-capacity but low-affinity, explaining the unpredictable insulin release pattern 2.
Epidemiology and Risk Factors
IAS occurs primarily in persons of Japanese or Korean ethnicity and significantly less frequently in Caucasians 1. The genetic susceptibility is strongly linked to specific HLA alleles, particularly HLA-DRB10406, DRB10403, and DRB1*0404 2, 4.
Common Triggers:
- Sulfhydryl-containing medications (methimazole is the classic drug trigger) 1, 4
- Alpha-lipoic acid supplementation (increasingly recognized as a major precipitant) 2, 4
- History of autoimmune diseases 1
- Monoclonal gammopathies and plasma cell dyscrasias 5
- Viral infections 3
Clinical Presentation
Patients present with recurrent hypoglycemic episodes occurring in the late postprandial period (typically 3-5 hours after meals), with neuroglycopenic symptoms including confusion, diaphoresis, tremor, and loss of consciousness 1, 2. The severity ranges from mild cases manageable with lifestyle changes to severe cases requiring intragastric glucose infusion 1.
Diagnostic Features
The diagnosis is readily made by finding high-titer serum insulin antibodies 1. Key diagnostic clues include:
Biochemical Findings During Hypoglycemia:
- Extremely elevated measured insulin levels (often >1000 µIU/mL), which may be artifactually high due to antibody interference with immunoassays 1, 2, 5
- Elevated C-peptide levels (confirming endogenous insulin production) 1
- Insulin-to-C-peptide ratio >1 6
- Negative sulfonylurea screen 5
Critical Diagnostic Pitfall:
The very high insulin levels can mimic insulinoma or factitious hypoglycemia, but insulin antibodies need not be measured at the time of hypoglycemia—they can be checked at any time to confirm the diagnosis 1. Polyethylene glycol precipitation can demonstrate antibody-bound insulin sequestration 5.
Distinguishing from Insulinoma:
- Negative imaging studies (CT, MRI, endoscopic ultrasound) 2
- Presence of high-titer insulin autoantibodies (absent in insulinoma)
- Discordant insulin-C-peptide results with disproportionately elevated insulin 2
Management
Most cases are self-remitting after withdrawal of the triggering agent, with supportive dietary measures forming the cornerstone of initial management 3, 6.
Treatment Algorithm:
Immediate measures:
Pharmacological therapy for persistent or severe cases:
- Acarbose (alpha-glucosidase inhibitor): Slows carbohydrate absorption, reducing postprandial insulin secretion 1, 4, 5
- Glucocorticoids: Suppress antibody production; typically achieve resolution within 4 weeks 5, 6
- Diazoxide: Inhibits pancreatic insulin secretion 1, 3
- Somatostatin analogues (octreotide): Reduce insulin secretion 3
- Immunosuppressive agents (azathioprine, rituximab): Reserved for refractory cases 3
Monitoring:
Prognosis:
Withdrawal of triggering agents combined with appropriate supportive and pharmacological management is associated with favorable prognosis in most patients, with complete resolution and sustained remission typical 4, 6.